Ноябрь/декабрь 2012, том 2, номер 3

<<< Вернуться к содержанию

■ Обзоры литературы

Майданник В.Г. Азитромицин: клинические аспекты применения в педиатрической практике. Международный журнал педиатрии, акушерства и гинекологии 2012;Т2(3):70-81

Азитромицин: клинические аспекты применения в педиатрической практике

Майданник В.Г.

Национальный медицинский университет имени А.А. Богомольца, Киев, Украина

■ Резюме:

Открытие и внедрение в клиническую практику азитромицина, антибиотика из группы макролидов, явилось одним из важнейших достижений в области антимикробной терапии. Азитромицин является одним из наиболее часто назначаемых макролидов, что обусловлено рядом его уникальных фармакокинетических и фармакодинамических свойств. В представленном обзоре дана характеристика азитромицина с позиций клинической фармакологии и клинической микробиологии с учётом положений доказательной медицины, а также результатов его практического применения в педиатрической практике для лечения целого ряда инфекционных заболеваний.

■ Ключевые слова:

азитромицин, фармакокинетика, спектр активности, показания к применению, обзор

■ Литература:

1. Майданник В.Г. Современные макролиды и их применение в клинической практике. К.:ВБ «Аванпост-Прим», 2012.-326 с.

2. Zuckerman J.M., Qamar F., Bono B.R. Review of Macrolides (Azithromycin, Clarithromycin), Ketolids (Telithromycin) and Glycylcyclines (Tigecycline).Med Clin N Am 2011; 95(4):761–791.

3. Веселов А.В., Козлов Р.С. Азитромицин: современные аспекты клинического применения. Клин микробиол антимикроб химиотер. 2006;8(1):18-32.

4. Piscitelli S.C., Danziger L.H., Rodvold K.A. Clarithromycin and azithromycin: new macrolide antibiotics. Clin Pharm 1992;11(2):137–152.

5. Sturgill M.G., Rapp R.P. Clarithromycin: review of a new macrolide antibiotic with improved microbiologic spectrum and favorable pharmacokinetic and adverse effect profiles. Ann Pharmacother 1992;26(9):1099–1108.

6. Hansen L.H., Mauvais P., Douthwaite S. The macrolide-ketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA. Mol Microbiol 1999;31(2):623–631.

7. Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis 2002; 34:482-492.

8. Зубков М.Н. Современные проблемы резистентности пневмотропных патогенов. Пульмонология. 2007; (5):5-13.

9. Shain C.S., Amsden G.W. Telithromycin: the first of the ketolides. Ann Pharmacother 2002;36(3):452–464.

10. Carbone C., Poole M.D. The role of newer macrolides in the treatment of community-acquired respiratory tract infections. A review of experimental and clinical data. J Chemother 1999; 11:107-118.

11. Козлов Р.С, Сивая О.В., Шпынев К.В. и соавт. Антибиотикорезистентность Streptococcus pyo- genes в России: результаты многоцентрового проспективного исследования ПеГАС-1. Клин микробиол антимикроб химиотер 2005; 7:154-166.

12. Richter S.S., Heilmann К.P., Beekmann S.E. et al. Macrolide-resistant Streptococcus pyogenes in the United States, 2002-2003. Clin Infect Dis 2005; 41:599-608.

13. Foulds G., Luke D.R., Teng R. et al. The absence of an effect of food on the bioavailability of azithromycin administered as tablets, sachet or suspension. J Antimicrob Chemother 1996;37(Suppl C):37–44.

14. Chandra R., Liu P., Breen J.D. et al. Clinical pharmacokinetics and gastrointestinal tolerability of a novel extended-release microsphere formulation of azithro- mycin. Clin Pharmacokinet 2007;46(3):247–259.

15. Nahata M.C., Koranyi K.I., Gadgil S.D. et al. Pharmacokinetics of azithromycin in pediatric patients after oral administration of multiple doses of suspen- sion. Antimicrob Agents Chemother 1993; 37:314-16.

16. Nahata M.C., Koranyi K.I., Luke D.R. et al. Pharmacokinetics of azithromycin in pediatric patients with acute otitis media. Antimicrob Agents Chemother 1995; 39:1875-1877.

17. Jacobs R.F., Maples H.D., Aranda J.V. et al. Pharmacokinetics of intravenously administered azithromycin in pediatric patients. Pediatr Infect Dis J 2005; 24:34-39.

18. Foulds G., Shepard R.M., Johnson R.B. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990;25(Suppl A):73–82.

19. Fraschini F., Scaglione F., Pintucci G. et al. The diffusion of clarithromycin and roxithromycin into nasal mucosa, tonsil and lung in humans. J Antimicrob Chemother 1991;27(Suppl A):61–65.

20. Rodvold K.A., Gotfried M.H., Danziger L.H. et al. Intrapulmonary steady-state concentrations of clarithromy- cin and azithromycin in healthy adult volunteers. Antimicrob Agents Chemother 1997;41(6):1399–1402.

21. Ballow C.H., Amsden G.W. Azithromycin: the first azalide antibiotic. Ann Pharmacother 1992;26(10):1253–1261.

22. Westphal J.F. Macrolide -induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol 2000;50(4):285–295.

23. Mazzei T., Surrenti C., Novelli A. et al. Pharmacokinetics of azithromycin in patients with impaired hepatic function. J Antimicrob Chemother 1993;31(Suppl E):57–63.

24. Mendes C.M., Sinto S.I., Oplustil C.P. et al. In vitro sus- ceptibility of gram-positive cocci isolated from skin and respiratory tract to azithromycin and twelve other antimicrobial agents. Braz J Infect Dis 2001; 5:269-276.

25. Delmee M., Carpenter M., Glupczynski Y. et al. In vitro susceptibilities of 180 clinical isolates of Haemophilus influenzae to ampicillin, amoxicillin/clavulanate, cefaclor, cefuroxime, cefotaxime, clarithromycin and azithromycin. Acta Clin Belg 1996; 51:237-243.

26. Trautmann M., Riediger C., Moricke A. et al. Combined activity of azithromycin and lansoprazole against Helicobacter pylori. Helicobacter 1999; 4:113-120.

27. Renaudin H., Bebear C. Comparative in vitro activity of azithromycin, clarithromycin, erythromycin and lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum. Eur J Clin Microbiol Infect Dis 1990; 9:838-841.

28. Lefevre J.C., Escaffre M.C., Courdil M., Larens M.B. In vitro evaluation of activities of azithromycin, clarithromycin and sparfloxacin against Chlamydia trachomatis. Pathol Biol 1993; 41:313-315.

29. Welsh L., Gaydos C, Quinn T.C. In vitro activities of azithromycin, clarithromycin, erythromycin and tetracycline against 13 strains of Chlamydia pneumoniae. Antimicrob Agents Chemother 1996; 40:212-214.

30. Aydin D., Kucukbasmaci O., Gonullu N., Aktas Z. Susceptibilities of Neisseria gonorrhoeae and Ureaplasma urealyticum isolates from male patients with urethritis to several antibiotics including telithromy- cin. Chemo¬therapy 2005; 51:89-92.

31. Stout J.E., Sens K., Mietzner S. Comparative activity of quinolones, macrolides and ketolides against Legionella species using in vitro broth dilution and intracellular susceptibility testing. Int J Antimicrob Agents 2005; 25:302-7.

32. Cantin L., Chamberland S. In vitro evaluation of the activities of azithromycin alone and combined with pyrimethamine against Toxoplasma gondii. Antimicrob Agents Chemother 1993; 37:1993-1996.

33. Mortensen J.E., Rodgers G.L. In vitro activity of gemifloxacin and other antimicrobial agents against isolates of Bordetella pertussis and Bordetella parapertussis. J Antimicrob Chemother 2000; 45(Suppl l):47-49.

34. Hunfeld K.P., Kraiczy P., Wichelhaus T.A. et al. Colorimetric in vitro susceptibility testing of penicillins, cephalosporins, macrolides, streptogramins, tetracy- clines, and aminoglycosides against Borrelia burgdor- feri isolates. Int J Antimicrob Agents 2000; 15:11-17.

35. Ohrt C, Willingmyre G.D., Lee P. et al. Assessment of azithromycin in combination with other antimalarial drugs against Plasmodium falciparum in vitro. Antimicrob Agents Chemother 2002; 46:2518-2524.

36. Bermudez L.E., Yamazaki Y. Effects of macrolides and ketolides on mycobacterial infections. Curr Pharm Des 2004; 10:3221-3228.

37. O'Sullivan N., Wise R. Macrolide, lincosamide and streptogramin antibiotics. Cur. Opin. Infect. Dis. 1990; 3: 743-750.

38. Garcia-Rodriguez J., Bellido J. et al. In vitro activities of new macrolides and rifapentine against Brucella spp. Antimicrob. Agents Chemother 1993; 37: 911—915.

39. Фомина И.П., Смирнова Л.Б., Юдин С.М. Азитромицин (сумамед) — в лечении инфекций дыхательных путей. Антибиотики и химиотерапия 1996; 41(2): 52—61.

40. Arguedas A., Emparanza P., Schwartz R.H. et al. A randomized, multicenter, double blind, double dummy trial of single dose azithromycin versus high dose amoxicillin for treatment of uncomplicated acute otitis media. Pediatr Infect Dis J 2005;24(2):153–161.

41. Murray J.J., Emparanza P., Lesinskas E. et al. Efficacy and safety of a novel, single-dose azithromycin microsphere formulation versus 10 days of levofloxacin for the treat- ment of acute bacterial sinusitis in adults. Otolaryngol Head Neck Surg 2005;133(2):194–200.

42. Henry D.C., Riffer E., Sokol W.N. et al. Randomized double-blind study comparing 3- and 6-day regimens of azithromycin with a 10-day amoxicillin-clavulanate regimen for treatment of acute bacterial sinusitis. Antimicrob Agents Chemother 2003;47(9):2770–2774.

43. Kinasewitz G., Wood R.G. Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia. Eur J Clin Microbiol Infect Dis 1991;10(10):872–877.

44. Paris R., Confalonieri M., Dal Negro R. et al. Efficacy and safety of azithromycin 1 g once daily for 3 days in the treatment of community-acquired pneumonia: an open-label randomised comparison with amoxicillin- clavulanate 875/125 mg twice daily for 7 days. J Chemother 2008;20(1):77–86.

45. Drehobl M.A., De Salvo M.C., Lewis D.E. et al. Singledose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-tomoderate community-acquired pneumonia in adults. Chest 2005;128(4):2230–2237.

46. D’Ignazio J., Camere M.A., Lewis D.E. et al. Novel, singledose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired pneumonia in adults. Antimicrob Agents Chemother 2005;49(10):4035–4041.

47. Contopoulos-Ioannidis D.G., Ioannidis J.P., Chew P. et al. Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections. J Antimicrob Chemother 2001;48(5):691–703.

48. Panpanich R., Lerttrakarnnon P., Laopaiboon M. Azithromycin for acute lower respiratory tract infections. Cochrane Database Syst Rev 2008;1:CD001954.

49. Swanson R.N., Lainez-Ventosilla A., De Salvo M.C. et al. Once-daily azithromycin for 3 days compared with clarithromycin for 10 days for acute exacerbation of chronic bronchitis: a multicenter, double-blind, randomzed study. Treat Respir Med 2005;4(1):31–39.

50. Amsden G.W., Baird I.M., Simon S. et al. Efficacy and safety of azithromycin vs levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis. Chest 2003;123(3):772–777.

51. Zervos M., Martinez F.J., Amsden G.W. et al. Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis. Int J Antimicrob Agents 2007;29(1):56–61.

52. Vergis E.N., Indorf A., File T.M. Jr et al. Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial. Arch Intern Med 2000;160(9):1294–1300.

53. Plouffe J., Schwartz D.B., Kolokathis A. et al. Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with communityac- quired pneumonia: the Azithromycin Intravenous Clinical Trials Group. Antimicrob Agents Chemother 2000;44(7):1796–1802.

54. Feldman R.B., Rhew D.C., Wong J.Y. et al. Azithromycin monotherapy for patients hospitalized with community-acquired pneumonia: a 31/2-year experience from a veterans affairs hospital. Arch Intern Med 2003;163(14):1718–1726.

55. Zervos M., Mandell L.A., Vrooman P.S. et al. Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia. Treat Respir Med 2004;3(5):329–336.

56. Frank E., Liu J., Kinasewitz G. et al. A multicenter, open-abel, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. Clin Ther 2002;24(8):1292–1308.

57. Correa J.C., Badaro R., Bumroongkit C. et al. Randomized, open-label, parallelgroup, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization. Clin Ther 2003;25(5):1453–1468.

58. Weiss K., Low D.E., Cortes L. et al. Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults. Can Respir J 2004;11(8):589–593.

59. GarciaVazquez E., Mensa J., Martinez J.A. et al.Lowermortalityamong patients with community-acquiredpneumonia treatedwith amacrolideplus a beta-lactamagent versus a beta-lactamagent alone. Eur J Clin Microbiol Infect Dis 2005;24(3):190–195.

60. Martinez J.A., Horcajada J.P., Almela M. et al. Addition of a macrolide to a betalactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003;36(4):389–395.

61. Plouffe J.F., Breiman R.F., Fields B.S. et al. Azithromycin in the treatment of Legionella pneumonia requiring hospitalization. Clin Infect Dis 2003;37(11):1475–1480.

62. Niederman M.S., Boss J., Campbell S. et al. American thoracic society guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assess¬ment of severity and critical antimicrobial therapy. Am. Rev. Respir. Dis. 1993; 148: 1418-1426.

63. Worm A., Osterlind M. Azithromycin levels in cervical mucus and plasma after a single Ig oral dose for chlamydial cervicitis. Genitourin Med. 1995;71:244—247.

64. Майданник В.Г. Внебольничные пневмонии у детей: Применение азитромицина с позиции доказательной медицины. Межд. журн. педиатр., акуш. и гинекол. 2012; 2(1): 95-111.

65. Dore M.P., Leandro G., Realdi G. et al. Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy:a meta-analytical approach. Dig Dis Sci 2000;45(1):68–76.

66. Buck M.L. Pediatric therapy update: azithromycin. Pediatric Pharmacotherapy 2005; 11(4).

67. Langley J.M., Halperin S.A., Boucher F.D. et al. Azithromycin is as effective as and better tolerated than erythromycin estolate for the treatment of pertussis. Pediatrics 2004; 114:96-101.

68. Miron D., Torem M., Merom R. et al. Azithromycin as an alternative to nalidixic acid in the therapy of childhood shigellosis. Pediatr Infect Dis J 2004; 23:367-368.

69. Frenck R.W., Mansour A., Nakhla I. et al. Short-course azithromycin for the treatment of uncomplicated typhoid fever in children and adolescents. Clin Infect Dis 2004; 38:951-957.

70. Kapadia N., Talib A. Acne treated successfully with azithromycin. Int J Dermatol 2004; 43:766-767.

71. Ruuskanen O. Safety and tolerability of azithromycin in pediatric infectious diseases: 2003 update. Pediatr Infect Dis J 2004; 23:135-139.